Walker Neil, Yang Yaling, Kiparoglou Vasiliki, Pokhrel Subhash, Robinson Hayley, van Woerden Hugo
NIHR Oxford Biomedical Research Centre, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LE, UK.
Nuffield Department of Primary Care Health Science, University of Oxford, Radcliffe Primary Care Building, Radcliffe Observatory Quarter, Woodstock Road, Oxford, OX2 6GG, UK.
BMC Health Serv Res. 2018 Mar 15;18(1):182. doi: 10.1186/s12913-018-2985-1.
Smoking cessation services provide support to smokers who desire to quit. Published studies to date have looked at the cost and benefit of service provision but typically focus on clinical trial data. Using routinely collected observational data, this study examined the costs involved in providing a service in terms of average health care expenditure per successful quit attempt in addition to population - level cost-effectiveness measures.
Data were analysed from Quit-51 smoking cessation service across five English regions between March 2013 and March 2016 (n = 9116). For each user, costs were estimated in relation to: (i) time spent with advisers; (ii) prescription of pharmacotherapy. The total costs compared against self-reported quit at 12 weeks, which represents the time period for which the service is offered. Cost per quit (CPQ), with 95% confidence interval (CI), was calculated by relating total expenditure to the number of quitters, firstly for the whole dataset and then by subgroups of key categorical variables, namely; gender, age group, the Fagerstrom test for nicotine dependence (FTND) and Index of Multiple Deprivation (IMD). Confidence intervals (CIs) for the mean estimates were derived using a non-parametric bootstrap procedure. Parameters derived from the calculation in relation to treatment were used to estimate potential long-term population outcomes under a scenario where the Quit 51 prescription was rolled out nationally.
The overall mean CPQ for this sample as estimated at 12 weeks was £403.51 (95% CI = £393.36 to £413.76). The estimated CPQs at this time point were comparable for those aged 12-19 (£423.56, 95% CI = £369.45 to £492.60) and those aged 20-29 (£430.76, 95% CI = £395.95 to £470.56). Differences were also seen in relation to other subgroups considered. The treatment parameters translated to a projected increase of 1.5 quality-adjusted life years (QALYs) per 1000 smokers in the short-term and 23.4 QALYS per 1000 smokers based on a lifetime horizon.
These figures throw light on service expenditure for each successful quit over the timeframe for which the service is offered in addition to highlighting variability in these costs across different subgroups of the user population.
戒烟服务为渴望戒烟的吸烟者提供支持。迄今为止已发表的研究探讨了服务提供的成本和效益,但通常侧重于临床试验数据。本研究使用常规收集的观察性数据,除了在人群水平上衡量成本效益外,还从每次成功戒烟尝试的平均医疗保健支出方面研究了提供该服务所涉及的成本。
分析了2013年3月至2016年3月期间英格兰五个地区的Quit-51戒烟服务数据(n = 9116)。对于每个用户,成本估计涉及:(i)与顾问相处的时间;(ii)药物治疗处方。将总成本与12周时自我报告的戒烟情况进行比较,12周是提供该服务的时间段。通过将总支出与戒烟者人数相关联来计算每次戒烟成本(CPQ)及其95%置信区间(CI),首先针对整个数据集,然后按关键分类变量的亚组进行计算,这些变量包括:性别、年龄组、尼古丁依赖的Fagerstrom测试(FTND)和多重剥夺指数(IMD)。使用非参数自助法得出平均估计值的置信区间(CI)。根据治疗计算得出的参数用于估计在全国范围内推广Quit 51处方的情况下潜在的长期人群结果。
该样本在12周时估计的总体平均CPQ为403.51英镑(95% CI = 393.36英镑至413.76英镑)。此时,12 - 19岁人群(423.56英镑,95% CI = 369.45英镑至492.60英镑)和20 - 29岁人群(430.76英镑,95% CI = 395.95英镑至470.56英镑)的估计CPQ相当。在所考虑的其他亚组中也存在差异。这些治疗参数转化为短期内每1000名吸烟者预计增加1.5个质量调整生命年(QALY),基于终生视角每1000名吸烟者增加23.4个QALY。
这些数据揭示了在提供服务的时间范围内每次成功戒烟的服务支出情况,同时突出了不同用户亚组之间这些成本的差异。